POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Clinical trials for POORLY DIFFERENTIATED THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new POORLY DIFFERENTIATED THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for POORLY DIFFERENTIATED THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis phase II trial tests a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—in 11 patients with advanced thyroid cancer that no longer responds to radioactive iodine or prior targeted therapy. The goal is to see if this mix can shrink tumors or stop them from g…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 12:05 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control OngoingThis phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer,…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
New drug combo shows promise for aggressive thyroid cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with advanced anaplastic or poorly differentiated thyroid cancer live longer. About 50 adults with cancer that cannot be removed by surgery or has spread will receive differe…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
New combo therapy shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis study tests whether the drug trametinib can make radioactive iodine treatment more effective for people with advanced thyroid cancer that has stopped responding to standard therapy. About 34 adults with certain genetic types of thyroid cancer will receive trametinib followed…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New drug combo shows promise for tough thyroid cancers
Disease control OngoingThis study tests whether a drug called PDR001, combined with either trametinib or dabrafenib, is safe and effective for people with thyroid cancer that no longer responds to radioactive iodine therapy. The trial includes 19 adults with certain types of advanced thyroid cancer. Re…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New drug shrinks thyroid tumors before surgery in early trial
Disease control OngoingThis study tests whether taking selpercatinib before surgery can shrink thyroid tumors that have a specific genetic change (RET alteration). About 30 people with advanced or recurrent thyroid cancer will receive the drug before their operation. The goal is to make surgery more ef…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New drug combo shows promise against rare, aggressive thyroid cancer
Disease control OngoingThis study tests a combination of two drugs, lenvatinib and pembrolizumab, in 25 people with advanced anaplastic thyroid cancer that cannot be removed by surgery or has spread. Lenvatinib blocks enzymes that help cancer cells grow, while pembrolizumab helps the immune system atta…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC